Linked Data API

Show Search Form

Search Results

916588
registered interest false more like this
date less than 2018-06-04more like thismore than 2018-06-04
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Leukaemia: Ibrutinib more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what estimate NHS England has made of the number of people with relapsed or refractory chronic lymphocytic leukaemia who will not receive ibrutinib as a result of the treatment’s Blueteq Approval Criteria published on the National Cancer Drugs Fund List. more like this
tabling member printed
Lord Mendelsohn more like this
uin HL8294 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p>An estimate of the number of patients with chronic lymphocytic leukaemia who will not receive treatment is not available. NHS England has advised that 828 patients with chronic lymphocytic leukaemia were registered to receive ibrutinib in 2017/18.</p> more like this
answering member printed Lord O'Shaughnessy more like this
question first answered
remove filter
answering member
4545
label Biography information for Lord O'Shaughnessy more like this
tabling member
4286
label Biography information for Lord Mendelsohn more like this